Skip to main content
SRTA logo

SRTA · Strata Critical Medical, Inc.

Track SRTA — free
$5.32 -0.20 (-3.54%)
Market Cap
$487.45M
Shares
88.47M
Volume · Nov 16 399.21K Avg daily vol (3M) 966.18K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.51 Open$5.77 Day$5.50–5.78 52W close$4.03–6.47 Avg vol 30d1.1M Short int4.6M · 5.1% of shares · 5.0d Short vol33% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Mar 2, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 10
Investor event
Transplant expansion drives margin gains and 60% cash conversion

Strata achieved its 13% organic margin target and expects about 60% free cash flow conversion in 2026, while expanding an end-to-end transplant clinical platform through acquisitions and national logistics scale.

3 source passages
Strata has tried to put all the pieces together in a single integrated offering to partner with transplant centers That was like on an organic basis of a 13% margin, which we achieved in the latest quarter because of all the clinical acquisitions that we've done. We got it to a 60% to 70% range at our investor day last year. We're going to do about 60% in 2026, and that should go higher towards the high end of the range moving forward. Open the document at this passage
Nov 3
Earnings call
Revenue rose 50.3%, free cash flow reached $8.6 million

Strata Critical Medical reported Q3 2026 revenue of $74.1 million, up 50.3%, adjusted EBITDA of $9.6 million and free cash flow of $8.6 million. It reiterated 2026 guidance and announced a $20 million share repurchase authorization.

5 source passages
Total revenue increased 50.3% to $74.1 million in Q3-2026 versus $49.3 million in the prior year period, driven by clinical acquisitions and growth, partially offset by logistics. Adjusted EBITDA increased both year-over-year and sequentially to $9.6 million in Q3 2026 versus $4.2 million in Q3 2025 and $7.9 million in Q2 2026. Free cash flow was strong at $8.6 million and benefited from a low level of aircraft capitalized maintenance, resulting in only $0.8 million of capital expenditures in the quarter. We are reiterating all aspects of our 2026 guidance, including revenue of $285 to $295 million, adjusted EBITDA of $33 to $35 million, and free cash flow before aircraft and engine acquisitions of $15 to $22 million. To that end, today we announced a $20 million share repurchase authorization, allowing us to take advantage of what we see as an attractive valuation for our own stock. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows 64.1% as Clinical expansion lifts gross margin

Strata Critical Medical reported revenue of $214.0 million for the nine months ended September 30, 2026, up 64.1% from $130.4 million, as Clinical revenue reached $73.2 million and total gross margin increased to 21.6%.

Revenue $74.08M ▲ 50.3% Net loss $7.62M Diluted EPS -$0.09
Read from the MD&A section
3 source passages
For the nine months ended September 30, 2026 and 2025, revenue increased by $83.6 million, or 64.1%, from $130.4 million in 2025 to $214.0 million in 2026. Clinical revenue was $73.2 million in the current period, reflecting the acquisition of Keystone in mid-September 2025 and the acquisitions made in April and June 2026. Total gross margin | 22.7 % | 21.6 % | | 21.6 % | 20.5 % Open the document at this passage
Nov 3
Current report 8-K
Revenue rose 50.3% as Adjusted EBITDA reached $9.6 million

Strata Critical Medical reported Q3 2026 revenue of $74.1 million, up 50.3% year-over-year, and Adjusted EBITDA of $9.6 million. Free Cash Flow was $8.6 million, and the company announced a $20 million share repurchase authorization.

Financial results
5 source passages
Strata Critical Medical Announces Third Quarter 2026 Results Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 Adjusted EBITDA(1) of $9.6 million in Q3 2026; Adjusted EBITDA margin of 13.0% Free Cash Flow(1) was $8.6 million in Q3 2026 Announced $20 million share repurchase authorization; will be deployed along with continued M&A strategy execution Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$280.76M
Trailing 12 months
Net income (TTM)
−$24.81M
Trailing 12 months
Revenue growth YoY
+50.3%
Year over year
Operating margin
-6.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
0.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$35.14M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+7.1%
Year over year · more shares
Price change (1Y)
+12.7%
Trailing year
Short interest
5.1%
Latest settlement · 5.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. Strata posted Q2 revenue up 60.7% to $72.5M with strong clinical growth, closed three bolt-on acquisitions, and raised 2026 revenue guidance to $285–295M and adjusted EBITDA to $33–35M, while logistics growth and margin softened due to a one-customer volume reduction.

Bullish
  • + Closed three bolt-on acquisitions adding ~$20M revenue and $6.3M projected annualized adjusted EBITDA
  • + Adjusted EBITDA margin expanded 140 bps sequentially to 10.9% with $7.9M adjusted EBITDA
Bearish
  • − Logistics gross margin fell to 18.4% from 19.3% sequentially and below ~20% expectation; guided to only 18.5–20% for H2
  • − Logistics revenue headwind of ~3% from a non-exclusive customer reducing flying for one organ type
  • − Q3 logistics revenue expected to decline high single digits sequentially due to customer reduction and summer seasonality
  • − Logistics gross profit declined 1.3% YoY to $8.9M with gross margin down 160 bps to 18.4%

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +8%
above
Price vs 50-day avg +10%
above
RSI (14) 58
neutral
MACD trend Positive
52-week position 61%
mid-range
Momentum
relative strength
Neutral
1-month return +21%
trailing
6-month return −10%
trailing
YTD return +15%
this year
Relative strength −11%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Distributing
136 of 141 funds reported for Sep 30 · net -987.9K sh shares · +36 new
Insider flow Accumulating
Net +$10.0K over 90 days · 0% sells
Short interest Rising
5.14% of shares out · ▲ +0.3% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
141 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Excellent
Revenue growth +34%
Y/Y
Gross margin 21%
expanding
EPS growth +243%
Y/Y
Free cash flow $-58.5M
Buyback $19.8M
remaining
Balance sheet $31.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −34%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 1 of last 2
Latest guidance · from the Earnings Call filed Aug 4, 2026
2026
Adjusted EBITDA Non-GAAP Raised $33M – $35M
May 6, 2026 $29M – $33M changed to Aug 4, 2026 $33M – $35M
Free cash flow before aircraft acquisitions Non-GAAP $15M – $22M
2026 revenue guidance Raised $285M – $295M
May 6, 2026 $260M – $275M changed to Aug 4, 2026 $285M – $295M
prior FY $197.14M midpoint +47.1% Y/Y
second half of the year
Logistics gross margin 18.5% – 20%
2026 (assuming recent clinical acquisitions closed January 1, 20
Adjusted EBITDA (pro forma) Non-GAAP $36M – $38M
Previous outlook earlier release · from the Earnings Call filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

Free cash flow before aircraft and engine purchases · 2026 $15M – $22M
Guided vs delivered · last 2 settled
Revenue 2025
guided $185M – $195M
$197.14M Beat +3.8%
Revenue full year 2024
guided $240M – $250M
$146.82M Miss −40.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+8% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
58 Neutral
MACD trend
Positive Bullish
52-week position
61% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Distributing
136 of 141 funds reported for Sep 30 · net -987.9K sh shares · +36 new
Insider flow Accumulating
Net +$10.0K over 90 days · 0% sells
Short interest Rising
5.14% of shares out · ▲ +0.3% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
141 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $6 · 61% Range high $6
vs 200-day avg +8% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP 14.3M six months ended June 30, 2026 —
Adjusted EBITDA as a percentage of revenue non-GAAP 10.2% six months ended June 30, 2026 —
Adjusted SG&A non-GAAP 18.33M six months ended June 30, 2026 —
Adjusted SG&A as a percentage of Revenue non-GAAP 12.6% three months ended June 30, 2026 —
Clinical gross margin 26.1% the three months ended June 30, 2026 filing —
Clinical revenue growth excluding Clinical acquisitions completed in Q2 2026 non-GAAP 15.1% Q2 2026 vs. Q1 2026 —
Clinical revenue sequential growth 22.6% Q2 2026 vs. Q1 2026 —
Free cash flow non-GAAP 2.88M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities 5.69M
-314K Capitalized software development costs
-2.49M Purchase of property and equipment, net of proceeds from disposal
= Free cash flow 2.88M
Free Cash Flow, before aircraft and engine acquisitions non-GAAP 2.9M Q2 2026 —
Transplant Clinical revenue sequential growth 23.8% Q2 2026 vs. Q1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SRTA
Strata Critical Medical, Inc.
this stock
$487.45M +14.6% +34.3% — 5.1%
HCA
HCA Healthcare, Inc.
$104.25B +6.9% +7.1% 16.6 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.34B +3.3% — — 0.0%
THC
Tenet Healthcare Corp
$22.76B +43.9% +0.9% 8.3 2.2%
EHC
Encompass Health Corp
$13.83B +32.8% +10.5% 22.0 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
163
% held
61.8%
Reported
136 of 141
Top holder
Third Point LLC
Held Float
View
Held by Funds
Fund positions
136
View
Short & Settlement
Short Interest Rising
Shares short
4.6M
Days to cover
5.0d
Change
+12.2K sh
View
Short Volume
Short vol %
33%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$7.9K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
29.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$10.0K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$197.1M
Net income (FY)
$41.3M
EPS diluted
$0.50
View
Buybacks
Authorized
$20.0M
Remaining
$19.8M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
16

Strata achieved its 13% organic margin target and expects about 60% free cash flow conversion in 2026, while expanding an end-to-end transplant clinical platform through acquisitions and national logistics scale.

View
Proposed Sales
Value
$517.0K
Shares
100.0K
Filed
Oct 2, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Strata Critical Medical Announces…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
SRTA -0.9% +21.4% -10.3% +24.1% +14.6%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -3.5% +22.5% -10.8% +24.3% +3.9%

Capital returns

Buyback program · as of Mar 31, 2025
Authorized
$20.00M
Spent (derived)
$200,000
Remaining
$19.80M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1779128 CUSIP 092667104 13F (30d) 129 filings 112 filers Visit website Investor relations